Perbak Capital Partners LLP BIO — BIO RAD LABS INC

Ownership history in Perbak Capital Partners LLP  ·  6 quarters on record

AI Ownership Summary

Perbak Capital Partners LLP reported BIO RAD LABS INC (BIO) in 6 quarterly 13F filings from 2023 Q4 through 2025 Q4. Peak portfolio weight reached 1.03% in 2023 Q4. The latest visible filing shows BIO at 1.03% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this BIO ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Perbak Capital Partners LLP's position in BIO RAD LABS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

BIO was reported at 1.03% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
1.03% in 2023 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

BIO stock page Perbak Capital Partners LLP fund profile Perbak Capital Partners LLP full holdings
How Perbak Capital Partners LLP held BIO — position size vs. price
% of Fund (quarterly)    BIO price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 6 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 ADDED — — — 11,121 +2,539 +29.6% 1.03% $3.4M 2026-02-17 $264.93
2025 Q3 ADDED — — — 8,582 +5,423 +171.7% 0.42% $2.4M 2025-11-13 $316.89
2025 Q2 ADDED — — — 3,159 +2,234 +241.5% 0.17% $762K 2025-08-14 $287.21
2025 Q1 REDUCED 78.0% -0.9% ✅ 925 -3,274 -78.0% 0.17% $225K 2025-05-15 $243.19
2024 Q4 REDUCED 62.2% -25.9% ✅ 4,199 -6,922 -62.2% 0.74% $1.4M 2025-02-14 $277.16
2023 Q4 INITIATED — — — 11,121 — — 1.03% $3.4M 2024-02-14 $327.91

🏢 Other funds also holding BIO

As of 2026 Q1 — sorted by position size

QVIDTVM Management LLC 3Y 28.68% JNE Partners LLP 3Y 10.5% Tikvah Management LLC 3Y 7Y 8.45% Hound Partners, LLC 3Y 7Y 3.41% MANGROVE PARTNERS IM, LLC 3Y 7Y 2.86% ARIEL INVESTMENTS, LLC 3Y 7Y 2.45% SOUTHEASTERN ASSET MANAGEMENT INC/TN/ 3Y 7Y 2.23% Sivik Global Healthcare LLC 3Y 7Y 2.12% Almitas Capital LLC 3Y 7Y 1.91% First Pacific Advisors, LP 3Y 7Y 1.59%

FAQ About Perbak Capital Partners LLP and BIO

These are the practical questions this page is built to answer before you even open the full history table.

How long has Perbak Capital Partners LLP reported owning BIO?

Perbak Capital Partners LLP reported BIO across 6 quarterly 13F filings, from 2023 Q4 through 2025 Q4.

What was the largest reported BIO position in Perbak Capital Partners LLP's portfolio?

The largest reported portfolio weight for BIO was 1.03% in 2023 Q4.

What is the latest reported BIO position on this page?

The most recent filing on this page is 2025 Q4, when Perbak Capital Partners LLP reported 11,121 shares, equal to 1.03% of portfolio, with an estimated market value of $3.4M.

What does the chart on this BIO ownership page compare?

The chart compares Perbak Capital Partners LLP's quarterly BIO portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Perbak Capital Partners LLP time their BIO position?

Based on 13F filing dates vs. subsequent BIO price moves, Perbak Capital Partners LLP correctly timed 2 out of 5 reported position changes (40%). The annualised alpha on BIO relative to SPY over the holding period was -15.5%.

← Back to Perbak Capital Partners LLP Holdings